Please wait...
|
|
Advisory Panel
| Dr. John Clancy John has over 40 years experience in the pharmaceutical sciences, in both academia and industry. He specialises in the development, analysis and stability of pharmaceuticals, both conventional and biotech based. John is particularly interested and experienced in addressing the technical issues which arise at the interface between science and regulation in the global pharmaceutical community. He has lectured on professional courses on stability and regulatory affairs to scientists and engineers for many years. |
|
Dr. Ray Munden Ray has over 32 years working experience with GlaxoSmithKline (GSK) on the pharmaceutical development of novel chemical entities. He held a variety of managerial positions with responsibility for groups involved in developing formulations and analytical methods, stability testing, stability sample and facilities management, degradation chemistry and experimental design. Ray served on or chaired various GSK project teams at various times with responsibilities that included: overseeing the global pharmaceutical development for new chemical entities; setting global analytical standards for the company; improving the development process; developing a global procedure for analytical equipment qualification; producing a harmonised global excipients inventory. |
|
|
|
|
